The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer.
Aged
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Autophagy
/ drug effects
Cannabidiol
/ pharmacology
Carcinoma, Endometrioid
/ diagnosis
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Cisplatin
/ pharmacology
Cystadenocarcinoma, Serous
/ diagnosis
Drug Synergism
Endometrial Neoplasms
/ diagnosis
Female
Gene Expression Regulation, Neoplastic
Humans
Middle Aged
Progression-Free Survival
Receptor, Cannabinoid, CB1
/ antagonists & inhibitors
Receptor, Cannabinoid, CB2
/ antagonists & inhibitors
TRPV Cation Channels
/ antagonists & inhibitors
TRPV2
cannabidiol
chemo-resistance
endometrial cancer
migration
progression-free survival
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Jul 2020
29 Jul 2020
Historique:
received:
29
06
2020
revised:
23
07
2020
accepted:
29
07
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
20
2
2021
Statut:
epublish
Résumé
Several studies support, both in vitro and in vivo, the anti-cancer effects of cannabidiol (CBD), a transient receptor potential vanilloid 2 (TRPV2) ligand. TRPV2, often dysregulated in tumors, is associated with altered cell proliferation and aggressiveness. Endometrial cancer (EC) is historically divided in type I endometrioid EC and type II non-endometrioid EC, associated with poor prognosis. Treatment options with chemotherapy and combinations with radiation showed only limited efficacy. Since no data are reported concerning TRPV2 expression as well as CBD potential effects in EC, the aim of this study was to evaluate the expression of TRPV2 in biopsies and cell lines as well as the effects of CBD in in vitro models. Overall survival (OS), progression-free survival (PFS), cell viability, migration, and chemo-resistance have been evaluated. Results show that TRPV2 expression increased with the malignancy of the cancer tissue and correlated with shorter PFS (
Identifiants
pubmed: 32751388
pii: ijms21155409
doi: 10.3390/ijms21155409
pmc: PMC7432565
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Receptor, Cannabinoid, CB1
0
Receptor, Cannabinoid, CB2
0
TRPV Cation Channels
0
TRPV1 protein, human
0
TRPV2 protein, human
0
Cannabidiol
19GBJ60SN5
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Pharm. 2020 Jan 25;574:118916
pubmed: 31811927
Biochim Biophys Acta. 2009 Mar;1793(3):528-39
pubmed: 19321128
Cancer Res. 2010 Feb 1;70(3):1225-35
pubmed: 20103638
Endocrinology. 2010 Mar;151(3):921-8
pubmed: 20133454
Biochem Pharmacol. 2018 Nov;157:266-274
pubmed: 30195736
Cureus. 2018 Apr 23;10(4):e2521
pubmed: 29942724
Biomolecules. 2019 Jul 25;9(8):
pubmed: 31349651
FASEB J. 2012 Apr;26(4):1535-48
pubmed: 22198381
Arch Pathol Lab Med. 2014 May;138(5):595-601
pubmed: 24236805
Int J Cancer. 2015 Oct 15;137(8):1855-69
pubmed: 25903924
J Recept Signal Transduct Res. 2018 Oct - Dec;38(5-6):385-392
pubmed: 30569804
Br J Pharmacol. 2013 Jan;168(1):79-102
pubmed: 22594963
PLoS One. 2013 May 31;8(5):e64885
pubmed: 23741410
Cancers (Basel). 2019 Jun 05;11(6):
pubmed: 31195721
Lab Invest. 2020 Feb;100(2):186-198
pubmed: 31653969
Br J Pharmacol. 2011 Aug;163(7):1479-94
pubmed: 21175579
J Mol Med (Berl). 2012 Aug;90(8):925-34
pubmed: 22231745
J Clin Med. 2019 May 11;8(5):
pubmed: 31083561
Mol Pharmacol. 2006 Sep;70(3):897-908
pubmed: 16754784
Urology. 2010 Aug;76(2):509.e1-7
pubmed: 20546877
Oncotarget. 2016 Nov 22;7(47):77543-77557
pubmed: 27769052
Pharm Res. 2010 Oct;27(10):2162-74
pubmed: 20668920
Eur Urol. 2008 Sep;54(3):612-20
pubmed: 17977643
J Natl Compr Canc Netw. 2016 Jul;14(7):915-22
pubmed: 27407130
Leuk Lymphoma. 2003 Oct;44(10):1767-73
pubmed: 14692532
Oncol Lett. 2016 Jan;11(1):16-22
pubmed: 26834851
Br J Pharmacol. 2019 May;176(10):1384-1394
pubmed: 30019449
Mol Cancer Ther. 2013 Jan;12(1):69-82
pubmed: 23220503
Front Pharmacol. 2019 Oct 15;10:1198
pubmed: 31680972
Cell Commun Signal. 2018 Oct 16;16(1):68
pubmed: 30326911
Prog Chem Org Nat Prod. 2017;103:103-131
pubmed: 28120232
Int J Cancer. 2014 Jun 1;134(11):2534-46
pubmed: 24293211
Endocr Relat Cancer. 2016 Feb;23(2):R85-R111
pubmed: 26538531
Int J Mol Sci. 2018 Aug 21;19(9):
pubmed: 30134548
Cells. 2014 Feb 19;3(1):112-28
pubmed: 24709905
J Physiol Biochem. 2018 May;74(2):261-272
pubmed: 29441458
J Pancreat Cancer. 2019 Jan 25;5(1):1-7
pubmed: 30706048
Curr Oncol. 2016 Mar;23(2):S15-22
pubmed: 27022310
Int J Mol Sci. 2018 Aug 13;19(8):
pubmed: 30104481
J Surg Res. 2019 Mar;235:210-215
pubmed: 30691796
Ther Adv Med Oncol. 2019 Aug 01;11:1758835919866362
pubmed: 31413731
Mol Cancer Ther. 2011 Jan;10(1):90-103
pubmed: 21220494
Nat Rev Cancer. 2017 Sep;17(9):528-542
pubmed: 28751651
Med Oncol. 2014 Jul;31(7):17
pubmed: 24878697
Mol Oncol. 2015 Apr;9(4):906-19
pubmed: 25660577
Biomed Res Int. 2018 Dec 4;2018:1691428
pubmed: 30627539
Hum Reprod. 2015 Jun;30(6):1421-36
pubmed: 25820697
Cancer. 1981 Jun 1;47(11):2634-40
pubmed: 6167343
Oncotarget. 2017 May 27;8(43):74068-74095
pubmed: 29088769
Front Mol Neurosci. 2019 Jan 15;11:487
pubmed: 30697147
Anticancer Res. 2011 Nov;31(11):3799-807
pubmed: 22110202
Mol Cancer Ther. 2011 Jul;10(7):1161-72
pubmed: 21566064
Br J Pharmacol. 2005 Apr;144(8):1032-6
pubmed: 15700028
Breast. 2018 Oct;41:34-41
pubmed: 30007266
Carcinogenesis. 2013 Jan;34(1):48-57
pubmed: 23079154